MovDisordV3, Main, Exploration, bibRecord, 004933

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease

Identifieur interne : 004933 ( Main/Exploration ); précédent : 004932; suivant : 004934

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease

Auteurs : Robert A. Hauser [États-Unis] ; William C. Koller [États-Unis] ; Jean P. Hubble [États-Unis] ; Teresita Malapira [États-Unis] ; Karen Busenbark [États-Unis] ; C. Warren Olanow [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-05.

RBID : ISTEX:F3B0A6640466CA17CB2CB589CB9C65ADAC2B8968

Descripteurs français

Pascal (Inist)
- Antiparkinsonien, Arrêt traitement, Bromocriptine, Carbidopa, Chimiothérapie, Ergot dérivé, Evolution, Homme, Lévodopa, Parkinson maladie.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Bromocriptine, Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Carbidopa, Carbidopa (adverse effects), Carbidopa (therapeutic use), Chemotherapy, Disability Evaluation, Disease Progression, Double-Blind Method, Ergot derivatives, Evolution, Female, Human, Humans, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Levodopa/carbidopa, Long‐duration response, Male, Middle Aged, Neurologic Examination (drug effects), Neuroprotection, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Prospective Studies, Selegiline (adverse effects), Selegiline (therapeutic use), Substance Withdrawal Syndrome (diagnosis), Treatment withdrawal, Wash‐out.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Bromocriptine, Carbidopa, Levodopa, Selegiline.
- chemical , therapeutic use : Antiparkinson Agents, Bromocriptine, Carbidopa, Levodopa, Selegiline.
- diagnosis : Parkinson Disease, Substance Withdrawal Syndrome.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- Aged, Disability Evaluation, Disease Progression, Double-Blind Method, Female, Humans, Male, Middle Aged, Prospective Studies.

Abstract

Putative neuroprotective agents for Parkinson's disease can be assessed in untreated patients using progression of clinical disability as an index of disease progression. To avoid the confound associated with symptomatic therapy, progression of the underlying disease can be assessed by evaluating the progression of clinical disability from an untreated baseline to a final visit following wash‐out of symptomatic medication. In this type of analysis it is critical to use a wash‐out of sufficient duration to ensure elimination of symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients at days 1, 8, and 15 following discontinuation of levodopa/carbidopa and bromocriptine. Mean total Unified Parkinson's Disease Rating Scale scores (± standard error) increased (worsened) by 7.4 ± 1.5 from day 1 to day 15 (p <0.0001), 4.5 ± 1.2 from day 1 to day 8 (p = 0.0009), and 2.9 ± 1.0 from day 8 to day 15 (p = 0.01). We conclude that a wash‐out of at least 2 weeks is required to eliminate the symptomatic effects of levodopa/carbidopa and bromocriptine in patients with early Parkinson's disease.

Url:

https://api.istex.fr/document/F3B0A6640466CA17CB2CB589CB9C65ADAC2B8968/fulltext/pdf

DOI: 10.1002/1531-8257(200005)15:3<485::AID-MDS1010>3.0.CO;2-F

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Koller, William C" sort="Koller, William C" uniqKey="Koller W" first="William C." last="Koller">William C. Koller</name>
</author>
<author><name sortKey="Hubble, Jean P" sort="Hubble, Jean P" uniqKey="Hubble J" first="Jean P." last="Hubble">Jean P. Hubble</name>
</author>
<author><name sortKey="Malapira, Teresita" sort="Malapira, Teresita" uniqKey="Malapira T" first="Teresita" last="Malapira">Teresita Malapira</name>
</author>
<author><name sortKey="Busenbark, Karen" sort="Busenbark, Karen" uniqKey="Busenbark K" first="Karen" last="Busenbark">Karen Busenbark</name>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F3B0A6640466CA17CB2CB589CB9C65ADAC2B8968</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200005)15:3<485::AID-MDS1010>3.0.CO;2-F</idno>
<idno type="url">https://api.istex.fr/document/F3B0A6640466CA17CB2CB589CB9C65ADAC2B8968/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002936</idno>
<idno type="wicri:Area/Istex/Curation">002936</idno>
<idno type="wicri:Area/Istex/Checkpoint">003133</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Hauser R:time:course:of</idno>
<idno type="wicri:Area/Main/Merge">007230</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0269467</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C07</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000114</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002A92</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Hauser R:time:course:of</idno>
<idno type="wicri:Area/Main/Merge">007484</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10830413</idno>
<idno type="wicri:Area/PubMed/Corpus">003F79</idno>
<idno type="wicri:Area/PubMed/Curation">003F79</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003E47</idno>
<idno type="wicri:Area/Ncbi/Merge">000272</idno>
<idno type="wicri:Area/Ncbi/Curation">000272</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000272</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Hauser R:time:course:of</idno>
<idno type="wicri:Area/Main/Merge">006F90</idno>
<idno type="wicri:Area/Main/Curation">004933</idno>
<idno type="wicri:Area/Main/Exploration">004933</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Koller, William C" sort="Koller, William C" uniqKey="Koller W" first="William C." last="Koller">William C. Koller</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Miami, Miami, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hubble, Jean P" sort="Hubble, Jean P" uniqKey="Hubble J" first="Jean P." last="Hubble">Jean P. Hubble</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Ohio State University, Columbus, Ohio</wicri:regionArea>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Malapira, Teresita" sort="Malapira, Teresita" uniqKey="Malapira T" first="Teresita" last="Malapira">Teresita Malapira</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Busenbark, Karen" sort="Busenbark, Karen" uniqKey="Busenbark K" first="Karen" last="Busenbark">Karen Busenbark</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Kansas, Kansas City, Kansas</wicri:regionArea>
<placeName><region type="state">Kansas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mount Sinai School of Medicine, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-05">2000-05</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="485">485</biblScope>
<biblScope unit="page" to="489">489</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">F3B0A6640466CA17CB2CB589CB9C65ADAC2B8968</idno>
<idno type="DOI">10.1002/1531-8257(200005)15:3<485::AID-MDS1010>3.0.CO;2-F</idno>
<idno type="ArticleID">MDS1010</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Bromocriptine</term>
<term>Bromocriptine (adverse effects)</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Carbidopa</term>
<term>Carbidopa (adverse effects)</term>
<term>Carbidopa (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Disability Evaluation</term>
<term>Disease Progression</term>
<term>Double-Blind Method</term>
<term>Ergot derivatives</term>
<term>Evolution</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Levodopa/carbidopa</term>
<term>Long‐duration response</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Neuroprotection</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Prospective Studies</term>
<term>Selegiline (adverse effects)</term>
<term>Selegiline (therapeutic use)</term>
<term>Substance Withdrawal Syndrome (diagnosis)</term>
<term>Treatment withdrawal</term>
<term>Wash‐out</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Bromocriptine</term>
<term>Carbidopa</term>
<term>Levodopa</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Bromocriptine</term>
<term>Carbidopa</term>
<term>Levodopa</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term>
<term>Substance Withdrawal Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Disability Evaluation</term>
<term>Disease Progression</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Arrêt traitement</term>
<term>Bromocriptine</term>
<term>Carbidopa</term>
<term>Chimiothérapie</term>
<term>Ergot dérivé</term>
<term>Evolution</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Putative neuroprotective agents for Parkinson's disease can be assessed in untreated patients using progression of clinical disability as an index of disease progression. To avoid the confound associated with symptomatic therapy, progression of the underlying disease can be assessed by evaluating the progression of clinical disability from an untreated baseline to a final visit following wash‐out of symptomatic medication. In this type of analysis it is critical to use a wash‐out of sufficient duration to ensure elimination of symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients at days 1, 8, and 15 following discontinuation of levodopa/carbidopa and bromocriptine. Mean total Unified Parkinson's Disease Rating Scale scores (± standard error) increased (worsened) by 7.4 ± 1.5 from day 1 to day 15 (p <0.0001), 4.5 ± 1.2 from day 1 to day 8 (p = 0.0009), and 2.9 ± 1.0 from day 8 to day 15 (p = 0.01). We conclude that a wash‐out of at least 2 weeks is required to eliminate the symptomatic effects of levodopa/carbidopa and bromocriptine in patients with early Parkinson's disease.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Floride</li>
<li>Kansas</li>
<li>Ohio</li>
<li>État de New York</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</region>
<name sortKey="Busenbark, Karen" sort="Busenbark, Karen" uniqKey="Busenbark K" first="Karen" last="Busenbark">Karen Busenbark</name>
<name sortKey="Hubble, Jean P" sort="Hubble, Jean P" uniqKey="Hubble J" first="Jean P." last="Hubble">Jean P. Hubble</name>
<name sortKey="Koller, William C" sort="Koller, William C" uniqKey="Koller W" first="William C." last="Koller">William C. Koller</name>
<name sortKey="Malapira, Teresita" sort="Malapira, Teresita" uniqKey="Malapira T" first="Teresita" last="Malapira">Teresita Malapira</name>
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004933 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004933 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:F3B0A6640466CA17CB2CB589CB9C65ADAC2B8968
   |texte=   Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.